A new study has found that adults with depression who start treatment with newer antipsychotic medications may face a higher risk of death compared to those who add a second antidepressant instead. This discovery raises concerns about the safety of antipsychotics in managing depression.
Antipsychotics vs. Antidepressants: A Closer Look
Depression is usually treated with antidepressants, but not everyone responds well to their first medication. When this happens, doctors may switch to a different antidepressant or add another drug to improve treatment.
Some patients are prescribed newer antipsychotics like aripiprazole, quetiapine, or olanzapine as an additional treatment. However, these medications come with serious health risks, including weight gain, metabolic issues, and an increased risk of death.
Previous research has already shown that older adults with dementia who take antipsychotics have a 50% higher risk of death. This new study, published in PLOS ONE by researchers from Rutgers University and Columbia University, suggests that the risk may also extend to younger adults with depression.
What the Study Found
The researchers analyzed data from 39,582 Medicaid patients aged 25 to 64 who were treated between 2001 and 2010. These patients had all been prescribed a single antidepressant but later needed additional treatment.
The study compared two groups:
- One group added a second antidepressant.
- The other group started an antipsychotic.
The results showed that those who began antipsychotic treatment had a 45% higher risk of death than those who added a second antidepressant. This increased risk translated to one additional death for every 265 patients taking antipsychotics for one year.
Why These Findings Matter
While more research is needed, the study raises important concerns about the widespread use of antipsychotics for depression. These medications may not offer enough benefits to justify their risks, particularly when safer alternatives exist.
Another major issue is that many patients in the U.S. start antipsychotics too soon—before fully trying a single antidepressant for the recommended four to six weeks. This premature use of riskier medications goes against clinical guidelines and best practices.
What This Means for Patients and Doctors
The findings highlight the need for careful prescribing practices. Doctors should only consider newer antipsychotics as a last resort, after safer treatments have failed. Patients should discuss all options with their healthcare providers and understand the risks before starting any new medication.
As researchers continue studying the long-term effects of antipsychotics for depression, this study serves as a strong reminder: when it comes to mental health treatment, patient safety should always come first.
If you care about health, please read studies that scientists find a core feature of depression and this metal in the brain strongly linked to depression.
For more information about health, please see recent studies about drug for mental health that may harm the brain, and results showing this therapy more effective than ketamine in treating severe depression.
Copyright © 2025 Knowridge Science Report. All rights reserved.
